Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
2078-54-8
Molecular formula
C12H18O
Molecular weight
178.2707 g/mol
Drug class
Intravenous general anaestheticSedative-hypnotic
Mechanism of action
The mechanism is not fully understood; propofol is thought to produce anaesthetic and sedative effects by positively modulating inhibitory GABA activity at ligand-gated GABA-A receptors.
Indications / reported uses
Induction of general anaesthesia
Maintenance of general anaesthesia
Monitored anaesthesia care sedation in adults
Sedation in adults receiving regional anaesthesia
ICU sedation of intubated, mechanically ventilated adults
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information
Drug class, mechanism of action and general use cases
Drug class
General Anesthetic
Mechanism of action
The mechanism of action, like all general anesthetics, is poorly understood.
General use cases
Delirium
Pain
Psychomotor Agitation
Status Epilepticus
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Propofol Environmental Risk Assessment (ERA) (the Propofol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.